(LON:NUM ) said revenue for its third quarter to 30 June 2020 was materially ahead of each of the first two quarters of the financial year as more companies turned to capital raisings.
The stockbroking firm said investment banking had benefited from increased capital markets transaction volumes, which more than offset the decline in M&A deals and the prevalent absence of IPOs.
Shares in Numis Corporation were trading 1.84% higher at 317.75p on Friday morning.
The group said equity trading maintained the positive momentum achieved in the first half.
While market volumes declined from the elevated highs experienced during the peak of the COVID-19 crisis, this was more than offset by strong trading gains during the period, it said.
Numis said revenue for the final quarter of the year will be dependent upon market conditions which it expects will continue to be influenced, to an extent, by the COVID-19 situation.
“However, we currently have a good pipeline of transactions, and we expect revenue and profits for the second half will be ahead of the first half,” the group added in the update.
Follow News & Updates fromhere:
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.
(Sharecast News) - London stocks were well into positive territory at the close on Friday, with banks pacing the advance after well-received results from Barclays, as investors shrugged off news that the UK's economic recovery was stalling.
Vast Resources, the AIM-listed mining company, updated investors this week on progress at its Baita Plai mine in Romania and gave further insight into the accelerated production opportunity at the low-cost Cu mine.
Gunsynd, an investment firm operating within the natural resources sector, announced that it has invested C$0.25 million (around £0.146 million) into precious metals royalty and streaming company Empress Royalty Corp. The group said the move complements existing investments in the precious metals sector, adding new commodity exposure to silver.
Clinical stage drug development firm, Evgen Pharma, has been given the green light to kick-start its STAR trial which will investigate whether its lead asset, SFX-01, can reduce the severity, or prevent the onset of, acute respiratory distress syndrome in patients with suspected COVID-19.
Braveheart Investment Group, the AIM-listed investment firm, said its investee company, Pharm2Farm ("P2F"), will launch the sale of a new antiviral face mask that has a ‘kill rate’ of over 90% for up to 7 hours for COVID-19 by the end of the year.
London-listed Sensyne Health, the UK-based clinical AI company, announced that it has signed a research collaboration agreement with US pharmaceutical company Bristol Myers Squibb ("BMS"), marking its fourth successive partnership with a major pharma company.